Amylin (AMLN) Shares Up 7.5% Amid Byetta/Bydureon Data; CEO Says 'Very Confident' in Diabetes Treatments
Tweet
Share
E-mailGet Alerts AMLN Hot Sheet
Join SI Premium – FREE
Shares of Amylin Pharma (Nasdaq: AMLN) are now sitting at session highs following an appearance by the President and CEO Dan Bradbury on CNBC's Closing Bell.
Amylin shares are up about 7.5 percent Monday afternoon following bullish data on its Byetta and Bydureon diabetes treatments over the weekend.
Bradbury said he is "very confident" in Bydureon and expects an FDA decision sometime during the first half of 2012.
The exec also said the company is not currently for sale.
Amylin shares are up about 7.5 percent Monday afternoon following bullish data on its Byetta and Bydureon diabetes treatments over the weekend.
Bradbury said he is "very confident" in Bydureon and expects an FDA decision sometime during the first half of 2012.
The exec also said the company is not currently for sale.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Synaptics CFO resigns amid pending ON Semiconductor merger
- Cinemo, Dolby, and SmashLabs partner on in-car gaming system
- Docebo raises share buyback price to $25, extends offer deadline
Create E-mail Alert Related Categories
Corporate News, FDA, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
